Menu Search
Equities

CRISM' Therapeutics Corp

CRTX:LSE

CRISM' Therapeutics Corp

Actions
FinancialsOpen End and Miscellaneous Investment Vehicles
  • Price (GBX)5.25
  • Today's Change-0.25 / -4.55%
  • Shares traded14.73k
  • 1 Year change-85.35%
  • Beta0.3341
Data delayed at least 20 minutes, as of Jun 21 2024 14:49 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, CRISM' Therapeutics Corp increased its cash reserves by 20.97%, or 760.00k. Cash Flow from Investing totalled 34.93m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 2.77m for operations while cash used for financing totalled 31.45m.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.3746
Tangible book value per share0.3746
More ▼

Balance sheet in USDView more

CRISM' Therapeutics Corp has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 4.38m.
Current ratio7.23
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.